Physician profile
Rosa Bell
NPI 1891829073
$13,531.40
in general payments reported to CMS, 2019-2025
44 companies · $451 in 2025
The $451 reported for 2025 was more than what 77% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,832 · 2020: $1,062 · 2021: $3,220 · 2022: $1,294 · 2023: $770 · 2024: $903 · 2025: $451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,123.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $6,840.10 | 2019-2021 | |
| Sk Life Science, INC. | $1,254.22 | 2020-2025 | |
| Lilly USA, LLC | $606.23 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Abbvie INC. | $605.08 | 2021-2025 | Ubrelvy, Qulipta |
| Ucb, INC. | $490.06 | 2019-2025 | Fintepla |
| Horizon Therapeutics Plc | $388.51 | 2021-2023 | Uplizna |
| Eisai INC. | $312.94 | 2020-2024 | |
| Supernus Pharmaceuticals, INC. | $271.30 | 2019-2023 | Oxtellar Xr |
| Amgen INC. | $194.12 | 2020-2025 | Uplizna |
| Arbor Pharmaceuticals, INC. | $180.60 | 2019-2021 | |
| Amneal Pharmaceuticals LLC | $175.68 | 2021-2025 | Crexont, Rytary |
| Biogen, INC. | $170.13 | 2019-2025 | Leqembi |
| Genzyme Corporation | $149.90 | 2021-2022 | |
| Allergan, INC. | $140.78 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $134.69 | 2022 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rosa Bell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.